Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ruzengxiao is a Traditional Chinese Medicine (TCM) formulation developed and manufactured by Heilongjiang Tianlong Pharmaceutical, specifically indicated for the treatment of breast hyperplasia (lobular hyperplasia of the breast) and associated mastalgia. The medication is typically formulated as capsules or tablets and contains a complex mixture of herbal extracts, including *Radix Paeoniae Alba*, *Radix Bupleuri*, *Thallus Laminariae*, and *Spica Prunellae*. Its therapeutic action is attributed to the TCM principles of soothing the liver, regulating qi, resolving phlegm, and softening hardness to dissipate nodules. Pharmacologically, it is thought to modulate the endocrine system by balancing estrogen and progesterone levels, while also providing anti-inflammatory and analgesic effects to reduce breast pain and lump size.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ruzengxiao.